Prader-Willi Syndrome

📖 Wiki Page

disease1428 wordssynced 2026-04-02

Prader-Willi Syndrome

<table class="infobox infobox-disease">
<tr>
<th class="infobox-header" colspan="2">Prader-Willi Syndrome</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
Characteristic facial features: narrow forehead, almond-shaped eyes
</td>
</tr>
<tr>
<td class="label">Also Known As</td>
<td>Prader-Willi-Labhart Syndrome, PWS</td>
</tr>
<tr>
<td class="label">ICD-10</td>
<td>Q87.1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/176270" target="_blank">176270</a></td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant (imprinted); usually sporadic</td>
</tr>
<tr>
<td class="label">Gene Region</td>
<td>15q11.2-q13 (paternal allele)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>15q11.2</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Infancy (hypotonia); childhood (hyperphagia)</td>
</tr>
<tr>
<td class="label">Key Features</td>
<td>Infantile hypotonia, hyperphagia, obesity, intellectual disability, behavioral problems</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>1 in 10,000-30,000</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Growth hormone, strict diet control, behavioral therapy</td>
</tr>
</table>

Prader-Willi Syndrome

Introduction

Prader Willi Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Prader-Willi Syndrome

Introduction

Overview

Prader-Willi Syndrome (PWS) is a rare genetic disorder caused by loss of function of genes on the paternal chromosome 15q11.2-q13 region [@dampened]. The condition is characterized by a distinctive two-phase clinical presentation: infants present with severe hypotonia and feeding difficulties, while childhood onset brings hyperphagia (uncontrollable hunger) leading to severe obesity if not strictly managed [@unravelling].

First described by Swiss doctors Andrea Prader, Alexis Labhart, and Heinrich Willi in 1956, Prader-Willi syndrome affects approximately 1 in 10,000 to 1 in 30,000 individuals worldwide. The syndrome represents the most common known genetic cause of life-threatening obesity [@dampened].

Genetics and Pathophysiology

Genomic Imprinting

Prader-Willi syndrome provides another critical example of genomic imprinting in humans. The 15q11-q13 region contains multiple imprinted genes that are expressed in a parent-of-origin-specific manner:

Paternal-expressed genes: MKRN3, MAGEL2, NDN, SNORD116 (SNURF-SNRPN), and others
Maternal-expressed genes: Only OCA2 is maternally expressed in this region

Loss of the paternal allele results in Prader-Willi syndrome, while loss of the maternal allele causes Angelman syndrome (a related but distinct disorder) [@functional].

Genetic Mechanisms

| Mechanism | Frequency | Description |
|-----------|-----------|--------------|
| Paternal 15q11-q13 deletion | ~70% | Microdeletion on paternal chromosome |
| Maternal uniparental disomy | ~25% | Two maternal copies of chromosome 15 |
| Imprinting center defect | ~3-5% | Epigenetic silencing of paternal alleles |
| Translocation | <1% | Rare chromosomal rearrangements |

The SNORD116 cluster of small nucleolar RNAs (snoRNAs) appears particularly important in driving the PWS phenotype, especially the hyperphagia and behavioral characteristics [@circulating].

Key Genes and Their Functions

SNORD116 (HBII-85): Loss of this snoRNA cluster is strongly associated with hyperphagia and PWS phenotype
MKRN3: Encodes makorin ring finger protein 3, involved in pubertal timing
MAGEL2: Involved in circadian rhythm regulation and hypothalamic function
NDN (Necdin): Neuronal differentiation and survival
OCA2: Pigmentation; loss correlates with fair skin and light hair

Clinical Features

Phase 1: Infancy (Birth to ~2 years)

Neonatal Period

Severe hypotonia (floppy infant syndrome)
Poor sucking reflex and feeding difficulties
Failure to thrive
Delayed motor milestones
Distinctive facial features: almond-shaped eyes, narrow forehead, triangular mouth
Cryptorchidism (undescended testicles) in males
Weak cry and decreased activity

Characteristic Facial Features

Narrow bifrontal diameter
Almond-shaped palpebral fissures
Downturned triangular mouth
Full cheeks (in infancy)
Fair skin and light hair (compared to family)

Phase 2: Childhood (2 years onward)

Hyperphagia and Obesity

Onset typically between 2-6 years
Food-seeking behavior and obsession with food
Lack of satiety sensation
Chronic overeating leading to rapid weight gain
Food-related behavioral problems
Risk of life-threatening obesity if not controlled
Compulsive eating and food foraging

Neurocognitive Profile

Mild to moderate intellectual disability (IQ ~60-80)
Learning disabilities and cognitive challenges
Language development delays
Strengths in visual spatial abilities
Executive function deficits

Behavioral Manifestations

Temper outbursts and tantrums
Stubbornness and oppositional behavior
Compulsive behaviors (skin picking, hair pulling)
Attention deficits
Anxiety and mood instability
Sleep disorders
Psychiatric manifestations in adulthood

Phase 3: Adulthood

Continued hyperphagia (may improve with age)
Obesity-related complications (diabetes, cardiovascular disease)
Behavioral issues may improve but persist
Social and vocational challenges
Hypogonadism and infertility
Scoliosis risk
Osteoporosis risk

Diagnosis

Clinical Criteria

The clinical diagnosis involves recognition of the characteristic phenotype:

History of infantile hypotonia with poor feeding
Development of hyperphagia and food obsession
Characteristic facial features
Developmental delays and learning disabilities

Genetic Testing

Confirmation requires genetic testing:

[DNA methylation](/entities/dna-methylation) analysis: Detects absence of paternal-specific methylation pattern (~99% sensitive)

Chromosomal microarray (CMA): Identifies 15q11-q13 deletion (~70% of cases)

SNP array: Detects maternal uniparental disomy (~25%)

FISH: Can detect deletions

methylation-specific MLPA: Detects deletions and UPD

Differential Diagnosis

Other causes of childhood obesity
Angelman syndrome (related imprinting disorder)
Bardet-Biedl syndrome
Leptin deficiency
Hypothalamic tumors
Other intellectual disability syndromes

Management and Treatment

Multidisciplinary Approach

Management requires a team approach including:

Endocrinologist
Geneticist
Dietitian
Behavioral specialist
Occupational/physical therapist
Speech therapist
Psychiatrist/psychologist

Key Management Strategies

Dietary Management

Strict food portion control
Environmental food security (locked kitchens, restricted access)
Low-calorie diet
Regular weight monitoring
Family education and behavioral interventions
Vitamin and mineral supplementation

Growth Hormone Therapy

Improves linear growth
Increases lean body mass
Improves motor function
May improve cognitive development
Must be carefully monitored
Requires genetic confirmation before initiating

Behavioral Interventions

Structured routines
Cognitive behavioral therapy
Social skills training
Anger management
Reward systems for appropriate behavior
Addressing compulsions (skin picking)

Medical Management

Treatment of obesity complications
Sleep studies (sleep apnea common)
Orthopedic monitoring (scoliosis)
Hormone replacement therapy (hypogonadism)
Psychiatric medications as needed

Emerging Therapies

Setmelanotide (MC4R agonist): FDA-approved for rare genetic obesity disorders; being studied in PWS
Targeted genetic therapies under development
Hypothalamic dysfunction modulation approaches

Relationship to Neurodegenerative Diseases

While primarily a neurodevelopmental disorder, Prader-Willi syndrome shares interesting features with neurodegenerative conditions:

Shared Pathways

Hypothalamic dysfunction: Both PWS and various neurodegenerative diseases involve hypothalamic dysfunction

Sleep disorders: High prevalence of sleep disturbances parallels findings in neurodegeneration

Mitochondrial dysfunction: Emerging evidence suggests mitochondrial abnormalities in PWS

Inflammatory processes: Some evidence of systemic inflammation in PWS

Research Implications

Studying PWS provides insights into:

Hypothalamic regulation of appetite and satiety
Genomic imprinting mechanisms
Genetic causes of obesity
Neurodevelopmental disorders with behavioral components

Animal Models

Mouse models with paternal 15q11-q13 deletions recapitulate key features:

Neonatal lethality with paternal deficiency
Growth retardation
Behavioral abnormalities
Metabolic dysregulation

Prognosis

With early diagnosis and comprehensive management:

Life expectancy can be normal with appropriate care
Quality of life significantly improved with behavioral and medical management
Adult independence varies (some achieve semi-independence)
Obesity-related complications are the major cause of morbidity
Behavioral issues require ongoing support throughout life

External Links

<a href="https://www.ncbi.nlm.nih.gov/books/NBK1155/" target="_blank">GeneReviews: Prader-Willi Syndrome</a>
<a href="https://rarediseases.org/rare-diseases/prader-willi-syndrome/" target="_blank">NORD: Prader-Willi Syndrome</a>
<a href="https://www.pwsausa.org/" target="_blank">Prader-Willi Syndrome Association (USA)</a>
<a href="https://clinicaltrials.gov/ct2/results?cond=Prader-Willi+Syndrome" target="_blank">Clinical Trials for Prader-Willi Syndrome</a>
<a href="https://www.omim.org/entry/176270" target="_blank">OMIM: Prader-Willi Syndrome</a>
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Prader-Willi+syndrome" target="_blank">PubMed: Prader-Willi Syndrome</a>

Background

The study of Prader Willi Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

[Dampened surge in heart rate at respiratory event termination in children with Prader-Willi syndrome.](https://pubmed.ncbi.nlm.nih.gov/41691910/) (2026 May) - Sleep medicine
[Unravelling Narcolepsy: A Series of Complex Pediatric Cases.](https://pubmed.ncbi.nlm.nih.gov/41669756/) (2026 Apr) - Neurology. Clinical practice
[Functional Independence in Adults With Prader-Willi Syndrome: First Report Using the FIM Instrument.](https://pubmed.ncbi.nlm.nih.gov/41368943/) (2026 Apr) - American journal of medical genetics. Part A
[Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disorders.](https://pubmed.ncbi.nlm.nih.gov/41811759/) (2026 Mar 11) - The Journal of clinical endocrinology and metabolism
[Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.](https://pubmed.ncbi.nlm.nih.gov/41703984/) (2026 Mar) - Obesity (Silver Spring, Md.)

References

📖 View canonical wiki page →

Prader-Willi Syndrome

Prader-Willi Syndrome

Prader-Willi Syndrome

Introduction

Overview

Prader-Willi Syndrome

Prader-Willi Syndrome

Introduction

Overview

Genetics and Pathophysiology

Genomic Imprinting

Genetic Mechanisms

Key Genes and Their Functions

Clinical Features

Phase 1: Infancy (Birth to ~2 years)

Phase 2: Childhood (2 years onward)

Phase 3: Adulthood

Diagnosis

Clinical Criteria

Genetic Testing

Differential Diagnosis

Management and Treatment

Multidisciplinary Approach

Key Management Strategies

Emerging Therapies

Relationship to Neurodegenerative Diseases

Shared Pathways

Research Implications

Animal Models

Prognosis

See Also

External Links

Background

Recent Research (2024-2026)

References